Latest Insider Transactions at Galecto, Inc. (GLTO)
This section provides a real-time view of insider transactions for Galecto, Inc. (GLTO). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Galecto, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Galecto, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 15
2023
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
822,680
-27.58%
|
$0
$0.75 P/Share
|
|
Jul 31
2023
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
209,400
-8.82%
|
$628,200
$3.0 P/Share
|
|
Jul 25
2023
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
39,200
-2.09%
|
$78,400
$2.92 P/Share
|
|
Jul 13
2023
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
194,700
-5.46%
|
$389,400
$2.4 P/Share
|
|
Apr 17
2023
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
13,089
-0.37%
|
$13,089
$1.97 P/Share
|
|
Apr 14
2023
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
41,446
-1.15%
|
$41,446
$1.86 P/Share
|
|
Apr 13
2023
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
13,946
-0.38%
|
$13,946
$1.82 P/Share
|
|
Apr 12
2023
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
2,363
-0.06%
|
$2,363
$1.81 P/Share
|
|
Apr 11
2023
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
13,946
-0.38%
|
$13,946
$1.82 P/Share
|
|
Apr 10
2023
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
51,228
-1.37%
|
$51,228
$1.79 P/Share
|
|
Apr 06
2023
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
9,665
-0.26%
|
$19,330
$2.0 P/Share
|
|
Apr 05
2023
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
92,965
-2.44%
|
$185,930
$2.18 P/Share
|
|
Mar 22
2022
|
Hans T. Schambye Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+8.71%
|
$10,000
$2.15 P/Share
|
|
Mar 22
2022
|
Bertil Lindmark Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
14,604
+46.8%
|
$29,208
$2.16 P/Share
|
|
Dec 03
2021
|
Jonathan Freve Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
4,000
+25.0%
|
$8,000
$2.49 P/Share
|
|
Dec 03
2021
|
Garrett Winslow General Counsel |
BUY
Open market or private purchase
|
Direct |
2,000
+33.33%
|
$4,000
$2.48 P/Share
|
|
Nov 09
2021
|
Hans T. Schambye Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
4,500
+8.67%
|
$13,500
$3.5 P/Share
|
|
Nov 08
2021
|
Jonathan Freve Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
3,000
+27.27%
|
$9,000
$3.4 P/Share
|
|
Aug 18
2021
|
Jonathan Freve Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
3,000
+37.5%
|
$9,000
$3.92 P/Share
|
|
Jun 28
2021
|
Bertil Lindmark Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
2,000
+50.0%
|
$10,000
$5.26 P/Share
|
|
Jun 24
2021
|
Hans T. Schambye Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
3,000
+6.53%
|
$15,000
$5.11 P/Share
|
|
Jun 23
2021
|
Garrett Winslow General Counsel |
BUY
Open market or private purchase
|
Direct |
2,000
+50.0%
|
$8,000
$4.8 P/Share
|
|
Jun 23
2021
|
Jonathan Freve Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
2,000
+50.0%
|
$8,000
$4.74 P/Share
|
|
Nov 02
2020
|
Stephan Christgau Director |
BUY
Open market or private purchase
|
Indirect |
66,666
+10.88%
|
$999,990
$15.0 P/Share
|
|
Nov 02
2020
|
Stephan Christgau Director |
BUY
Conversion of derivative security
|
Indirect |
479,470
+50.0%
|
-
|
|
Nov 02
2020
|
Chau Quang Khuong Director |
BUY
Open market or private purchase
|
Indirect |
733,333
+16.88%
|
$10,999,995
$15.0 P/Share
|
|
Nov 02
2020
|
Chau Quang Khuong Director |
BUY
Conversion of derivative security
|
Indirect |
3,069,922
+50.0%
|
-
|
|
Nov 02
2020
|
Hans T. Schambye Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
13,931
+25.87%
|
-
|
|
Nov 02
2020
|
Amit Munshi |
BUY
Conversion of derivative security
|
Direct |
4,793
+50.0%
|
-
|
|
Nov 02
2020
|
Anders Pedersen Chief Operating Officer |
BUY
Conversion of derivative security
|
Direct |
3,746
+50.0%
|
-
|
|
Nov 02
2020
|
Carl Goldfischer |
BUY
Conversion of derivative security
|
Indirect |
1,039,468
+50.0%
|
-
|
|
Nov 02
2020
|
Carl Goldfischer |
BUY
Conversion of derivative security
|
Direct |
9,587
+50.0%
|
-
|
|
Nov 02
2020
|
Novo Holdings > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
333,333
+11.77%
|
$4,999,995
$15.0 P/Share
|
|
Nov 02
2020
|
Novo Holdings > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
2,164,458
+50.0%
|
-
|
|
Nov 02
2020
|
Orbimed Advisors LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
733,333
+16.88%
|
$10,999,995
$15.0 P/Share
|
|
Nov 02
2020
|
Orbimed Advisors LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
3,069,922
+50.0%
|
-
|